Home / Health / Breakthrough Treatment Transforms Debilitating Autoimmune Disease
Breakthrough Treatment Transforms Debilitating Autoimmune Disease
1 Mar
Summary
- A pioneering monthly injection, ianalumab, shows promise for Sjogren's syndrome.
- Ianalumab destroys immune cells attacking the body's moisture-producing glands.
- Clinical trials show rapid and significant reduction in Sjogren's symptoms.
A groundbreaking monthly injection, ianalumab, is showing remarkable results in transforming the lives of those with Sjogren's syndrome. This autoimmune disease, affecting an estimated 500,000 people in Britain, primarily impacts women aged 40-60 and causes dryness and joint pain.
Terry Aretz, diagnosed in January 2020, experienced debilitating fatigue and pain before finding relief. Ianalumab, which blocks and destroys immune cells attacking moisture-producing glands, has drastically improved her quality of life. Clinical trials demonstrate rapid symptom reduction, leading to a breakthrough therapy designation in the US.
Experts anticipate ianalumab could be available on the NHS within a few years. It represents the first targeted treatment for Sjogren's, potentially preventing and repairing long-term damage. While not without occasional side effects, like low moods for Terry, it offers a revolutionary hope for many.
Terry's access to the treatment came through a clinical trial six hours away. Within months, her saliva production increased by 60%, and she regained mobility. This pioneering drug, which may become widely available soon, allows patients to "participate in life again."
